X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
1. Cubicin
2. Daptomycin, 9 L Beta Aspartic Acid
3. Daptomycin, 9-l Beta-aspartic Acid
4. Deptomycin
5. Ly 146032
6. Ly-146032
7. Ly146032
1. 103060-53-3
2. Cubicin
3. Deptomycin
4. Cidecin
5. Daptomycine [french]
6. Daptomycinum [latin]
7. Daptomicina [spanish]
8. Schembl1650768
9. Akos026750170
| Molecular Weight | 1620.7 g/mol |
|---|---|
| Molecular Formula | C72H101N17O26 |
| XLogP3 | -5.1 |
| Hydrogen Bond Donor Count | 22 |
| Hydrogen Bond Acceptor Count | 28 |
| Rotatable Bond Count | 35 |
| Exact Mass | 1619.71036639 g/mol |
| Monoisotopic Mass | 1619.71036639 g/mol |
| Topological Polar Surface Area | 702 Ų |
| Heavy Atom Count | 115 |
| Formal Charge | 0 |
| Complexity | 3480 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 3 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Cubicin |
| PubMed Health | Daptomycin (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | CUBICIN contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus. The chemical name is N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L... |
| Active Ingredient | Daptomycin |
| Dosage Form | Injectable |
| Route | Iv (infusion) |
| Strength | 500mg/vial |
| Market Status | Prescription |
| Company | Cubist |
| 2 of 4 | |
|---|---|
| Drug Name | Daptomycin |
| PubMed Health | Daptomycin (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | CUBICIN contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus. The chemical name is N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L... |
| Active Ingredient | Daptomycin |
| Dosage Form | Injectable |
| Route | injection; Iv (infusion) |
| Strength | 500mg/vial; 350mg |
| Market Status | Tentative Approval; Prescription |
| Company | Hospira |
| 3 of 4 | |
|---|---|
| Drug Name | Cubicin |
| PubMed Health | Daptomycin (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | CUBICIN contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus. The chemical name is N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L... |
| Active Ingredient | Daptomycin |
| Dosage Form | Injectable |
| Route | Iv (infusion) |
| Strength | 500mg/vial |
| Market Status | Prescription |
| Company | Cubist |
| 4 of 4 | |
|---|---|
| Drug Name | Daptomycin |
| PubMed Health | Daptomycin (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | CUBICIN contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus. The chemical name is N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L... |
| Active Ingredient | Daptomycin |
| Dosage Form | Injectable |
| Route | injection; Iv (infusion) |
| Strength | 500mg/vial; 350mg |
| Market Status | Tentative Approval; Prescription |
| Company | Hospira |
Cubicin is indicated for the treatment of the following infections.
- Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).
- Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.
It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.
- Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.
Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J01XX09
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01X - Other antibacterials
J01XX - Other antibacterials
J01XX09 - Daptomycin
Market Place
